A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Learn more about:
Related Clinical Trial
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer Metabolic Stress-induced Exercise to Prevent Loss of Muscle Mass in Patients With Pancreatic and Biliary Tract Cancer The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer A Study of ABL001 in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy Predicting Disease Progression and/or Recurrence in Cancer Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis A Phase 1/2 Study of SC-43 in Combination With Cisplatin The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Unresectable Biliary Tract Cancer. A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer A Trial of SHR1258 in Patients With Biliary Tract Cancer Perception Prognosis, Goals of Treatment, and Communication IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Tremelimumab With Chemoembolization or Ablation for Liver Cancer Preoperative Nutritional Support in Malnutritional Cancer Patients Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions Early Palliative Care on Quality of Life of Advanced Cancer Patients Patient Activation Through Counseling, Exercise and Mobilization Extracellular RNA Markers of Liver Disease and Cancer X-MAS Biliary Study With Covered Biliary Stent A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors GTX Regimen for Biliary Cancers Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer FOLFIRINOX for 2nd-line Treatment of BTC Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Trastuzumab in HER2-positive Biliary Tract Cancer Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase Second Line Therapy in Advanced Biliary Tract Cancer Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer. Case Series Study of Biliary Tract Cancer Patients in Japan GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer Molecular Profiling of Advanced Biliary Tract Cancers MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer Allogeneic NK Cell (“SMT-NK”) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer Vessel Resection and Reconstruction of Biliary Tract Cancers Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) NGS as the First-line Treatment in Advanced Biliary Tract Cancer Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Molecular Profiling of Advanced Biliary Tract Cancers

Brief Title

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Official Title

A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Brief Summary

      This is a Phase I, open-label, multi-centre, drug combination study of double and triple
      combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral
      selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.
    

Detailed Description

      This is a Phase I, open-label, multi-centre, drug combination study of double and triple
      combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral
      selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours
      refractory to standard therapy or for which no standard therapy exists. The safety,
      tolerability, and preliminary anti-tumour activity of ascending doses of Selumetinib (AZD6244
      Hyd-sulfate) in Combination with MEDI4736 and Selumetinib in Combination with MEDI4736 and
      Tremelimumab will be investigated. Once safety and tolerability have been established for the
      relevant dose, expansion cohorts will commence in order to further evaluate safety,
      tolerability, and provide a preliminary evaluation of the mechanism of action and anti-tumour
      activity of the drug combination. Mandatory paired biopsy expansion cohorts will be
      tumour-type specific. Expansion cohorts will open independently for double and triple
      combination treatments.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events

Secondary Outcome

 Long-term tolerated dose and exposure predicted to result in biological activity (including but not limited to Response Evaluation Criteria in Solid Tumours (RECIST)

Condition

Lung Cancer

Intervention

Selumetinib

Study Arms / Comparison Groups

 Dose escalation: Selumetinib+MEDI4736
Description:  An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).
The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

58

Start Date

December 28, 2015

Completion Date

September 20, 2019

Primary Completion Date

July 25, 2018

Eligibility Criteria

        Inclusion Criteria:

          1. Written informed consent and any locally-required authorization (eg, Health Insurance
             Portability and Accountability Act in the US, EU Data Privacy Directive in the EU)
             obtained from the patient prior to performing any protocol-related procedures,
             including pre-screening and screening evaluations

          2. Age ≥18 years at time of study entry

          3. Histological or cytological confirmation of locally advanced (stage IIIB) or
             metastatic (stage IV) solid tumours refractory to standard therapy or for which no
             standard therapy exists

          4. World Health Organisation Eastern Cooperative Oncology Group (ECOG) performance status
             0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12
             weeks

          5. At least 1 lesion, not previously irradiated, that can be accurately measured at
             baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short
             axis ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and
             which is suitable for accurate repeated assessment as per Response Evaluation Criteria
             in Solid Tumours (RECIST criteria v1.1)

          6. Female patients and males with partners of childbearing potential should be using
             highly effective contraceptive measures. Females should not be breastfeeding and must
             have a negative pregnancy test prior to start of dosing if of childbearing potential
             or must have evidence of non-childbearing potential by fulfilling 1 of the criteria
             below at screening.

               -  Postmenopausal defined as aged more than 50 years and amenorrhoeic for at least
                  12 months following cessation of all exogenous hormonal treatments

               -  Women <50 years old would be considered postmenopausal if they have been
                  amenorrheic for the past 12 months or more following cessation of exogenous
                  hormonal treatments. The levels of luteinising hormone (LH) and follicle
                  stimulating hormone (FSH) must also be in the postmenopausal range (as per the
                  institution)

               -  Documentation of irreversible surgical sterilisation by hysterectomy and / or
                  bilateral oophorectomy and/or bilateral salpingectomy but not tubal ligation

          7. Male patients should be willing to use barrier contraception ie, condoms plus
             spermicide

          8. Mandatory provision of tumour tissue sample available at study entry for exploratory
             biomarker research. Cytology samples for this exploratory biomarker research will not
             be acceptable

          9. Patients must have mCRC and, if MSI status is known, non-high MSI status. MSI status
             will be evaluated based on previous results of local MSI testing, if available.
             Patients with known MSI-high status will be excluded; patients with MSS, MSI-low, or
             unknown MSI status may be enrolled

        Exclusion Criteria:

        Patients must not enter the study if any of the following exclusion criteria are fulfilled

          1. Previous enrolment in the present study

          2. Treatment with any of the following:

               -  Cytotoxic chemotherapy or other anticancer drugs within 28 days of the 1st dose
                  of study treatment or any investigational agents within 5 half-lives of the
                  product

               -  MEDI4736 or selumetinib in the present study (ie, dosing with MEDI4736 or
                  selumetinib previously initiated in this study)

               -  Major surgical procedure, (excluding placement of vascular access) or significant
                  traumatic injury within 4 weeks of the 1st dose of study treatment, or have an
                  anticipated need for major surgery during the study

               -  Palliative radiotherapy with a wide field of radiation within 4 weeks or
                  radiotherapy with a limited field of radiation for palliation within 2 weeks of
                  the 1st dose of study treatment

               -  Prior exposure to immune-mediated therapy, including, but not limited to, other
                  anti-CTLA- 4 (Cytotoxic T-lymphocyte antigen-4), anti-PD-1 (Programmed cell death
                  1), anti-PD-L1 (Programmed cell death ligand 1), or anti-PD-L2 (Programmed cell
                  death ligand 2) antibodies, including therapeutic anticancer vaccines

               -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP

               -  Concurrent enrolment in another clinical study, unless it is an observational
                  (non-interventional) clinical study or during the follow-up period of an
                  interventional study

          3. Any unresolved toxicity NCI CTCAE (National Cancer Institute Common Terminology
             Criteria for Adverse Events) Grade ≥2 from previous anticancer therapy with the
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
             criteria

               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis and
                  may be included after consultation with the medical monitor

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with selumetinib, MEDI4736 or tremelimumab may be included after
                  consultation with the medical monitor

          4. History of leptomeningeal carcinomatosis and brain metastases or spinal cord
             compression. Patients with suspected brain metastases at screening should have a CT /
             MRI of the brain prior to study entry

          5. Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the
             exception of diverticulosis], celiac disease, irritable bowel disease, or other
             serious GI (Gastrointestinal) chronic conditions associated with diarrhoea, systemic
             lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [eg, granulomatosis
             with polyangiitis, Graves' disease; rheumatoid arthritis, hypophysitis, uveitis])
             within the past 3 years prior to the start of treatment. The following are exceptions
             to this criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone
                  replacement or psoriasis not requiring systemic treatment

          6. History of active primary immunodeficiency

          7. Current or prior use of immunosuppressive medication within 14 days before the 1st
             dose of MEDI4736. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (eg,
                  intra-articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (eg, CT scan
                  premedication)

          8. As judged by the investigator, any evidence of severe or uncontrolled systemic
             diseases, including uncontrolled hypertension, renal transplant, active bleeding
             diatheses, which in the investigator's opinion makes it undesirable for the patient to
             participate in the study or which would jeopardise compliance with the protocol or
             active infection including hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody or human immunodeficiency virus (HIV) or known history of clinical
             diagnosis of tuberculosis

          9. Screening for chronic conditions is not required

         10. Any of the following cardiac criteria:

               -  Any factors that increase the risk of QT(ECG interval measured from the onset of
                  the QRS complex to the end of the T wave) interval corrected for heart rate (QTc)
                  prolongation or risk of arrhythmic events (eg, heart failure, hypokalaemia,
                  congenital long QT syndrome, family history of long QT syndrome or unexplained
                  sudden death under 40 years of age) or mean QTc >470 msec

               -  Uncontrolled hypertension (eg, BP ≥150/95 mmHg despite medical therapy)

               -  Acute coronary syndrome within 6 months prior to starting treatment

               -  Angina Canadian Cardiovascular Society Grade II-IV (despite medical therapy)

               -  Symptomatic heart failure (New York Heart Association II-IV)

               -  Prior or current cardiomyopathy

               -  Baseline LVEF (Left ventricular ejection fraction) <55% measured by
                  echocardiography or MUGA. Appropriate correction to be used if a MUGA is
                  performed.

               -  Atrial fibrillation with a ventricular rate >100 beats per minute at rest

               -  Severe valvular heart disease

         11. Any of the following ophthalmic criteria:

               -  Current or past history of central serous retinopathy, detachment of retinal
                  pigmented epithelium, or retinal vein occlusion

               -  Intraocular pressure (IOP) >21 mmHg

               -  Uncontrolled glaucoma (irrespective of IOP)

         12. Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

               -  Absolute neutrophil count <1.5 x 109/L

               -  Platelet count <100 x 109/L

               -  Haemoglobin <90 g/L

               -  Alanine aminotransferase >2.5 x ULN (upper limit of normal) if no demonstrable
                  liver metastases or >5 times ULN in the presence of liver metastases

               -  Aspartate aminotransferase >2.5 x ULN if no demonstrable liver metastases or >5
                  times ULN in the presence of liver metastases

               -  Serum bilirubin ≤1.5 x ULN. This will not apply to patients with confirmed
                  Gilbert's syndrome (persistent or recurrent hyperbilirubinaemia [predominantly
                  unconjugated bilirubin] in the absence of evidence of haemolysis or hepatic
                  pathology), who will be allowed in consultation with their physician

               -  Creatinine clearance <50 mL/min (calculated by Cockcroft and Gault equation).
                  Confirmation of creatinine clearance is only required when creatinine is >1.5
                  times ULN

         13. Refractory nausea and vomiting, chronic GI diseases, inability to swallow the
             formulated product or previous significant bowel resection that would preclude
             adequate absorption of selumetinib

         14. History of hypersensitivity to active or inactive excipients of MEDI4736 or
             selumetinib or drugs with a similar chemical structure or class to MEDI4736 or
             selumetinib

         15. Judgment by the investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions, and
             requirements

         16. Involvement in the planning and conduct of the study (applies to both AZ staff or
             staff at the study site)

         17. Previous allogeneic bone marrow transplant

         18. Body weight <30 kg
      

Gender

All

Ages

18 Years - 99 Years

Accepts Healthy Volunteers

No

Contacts

Pasi A. Jänne, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02586987

Organization ID

D1345C00003


Responsible Party

Sponsor

Study Sponsor

AstraZeneca


Study Sponsor

Pasi A. Jänne, MD, PhD, Principal Investigator, Dana-Farber Cancer Institute


Verification Date

November 2019